Viridian Therapeutics
VRDN
170 hedge funds and large institutions have $1.32B invested in Viridian Therapeutics in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 64 reducing their positions, and 28 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
7% more capital invested
Capital invested by funds: $1.23B → $1.32B (+$90.3M)
3.77% more ownership
Funds ownership: 112.12% → 115.89% (+3.8%)
3% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 64
3% less funds holding
Funds holding: 176 → 170 (-6)
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
70% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $5.96M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$23.7M |
| 2 |
CC
Commodore Capital
New York
|
+$17.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.4M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.77M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$12.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.1M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$6.07M |
| 4 |
Goldman Sachs
New York
|
-$4.5M |
| 5 |
Renaissance Technologies
New York
|
-$4.32M |
VRDN Hedge Fund Activity: Q2 2025 in Review
170 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2025, worth a combined $1.32B — up 7.3% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of VRDN and 22 opened new positions — a net loss of 6 holders — while 64 trimmed existing stakes and 62 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $23.7M. The largest seller was Driehaus Capital Management, cutting an estimated $12.1M.
- 170 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2025, down from 176 in Q1 2025.
- Funds reported $1.32B of Viridian Therapeutics stock for Q2 2025, up 7.3% quarter-over-quarter.
- 22 funds opened new Viridian Therapeutics positions in Q2 2025 and 28 closed out, a net change of -6 holders.
- The largest Viridian Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $23.7M added.
- The largest Viridian Therapeutics seller in Q2 2025 was Driehaus Capital Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2025.